Karyopharm Therapeut (KPTI) 10.62 $KPTI Karyoph
Post# of 273257
Posted On: 09/04/2016 7:25:49 AM
Karyopharm Therapeut (KPTI) 10.62 $KPTI
Karyopharm to Host Conference Call with Update on Multiple Myeloma Plans
GlobeNewswire - Tue Aug 30, 11:14AM CDT
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced it will provide an overview of top-line results from its Phase 2b STORM study and the planned development path for selinexor (KPT-330) in multiple myeloma (MM) on Tuesday, September 6, 2016, followed by a conference call on Tuesday, September 6, 2016 at 8:30 a.m., Eastern time. To access the conference call, please dial (855) 437-4406 (US) or (484) 756-4292 (international) at least five minutes prior to the start time and refer to conference ID: 74213103. Accompanying slides will be available under "Events & Presentations" in the "Investor" section of Karyopharm's website, http://www.karyopharm.com, where an audio recording of the call will be available approximately two hours after the event.
KPTI: 10.62 (-0.48)
Karyopharm Reports Second Quarter 2016 Financial Results and Highlights Recent Progress
GlobeNewswire - Thu Aug 04, 6:30AM CDT
Completed Enrollment in Phase 2b STORM Clinical Trial for Refractory Multiple Myeloma
KPTI: 10.62 (-0.48)
Karyopharm to Present at Upcoming Investor Conferences
GlobeNewswire - Wed Aug 03, 6:30AM CDT
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that members of the management team will present at the following upcoming investor conferences:
KPTI: 10.62 (-0.48)
Karyopharm to Report Second Quarter 2016 Financial Results on August 4, 2016
GlobeNewswire - Thu Jul 28, 7:00AM CDT
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that it will report second quarter 2016 financial results and provide a company update on Thursday, August 4, 2016. Karyopharm's management team will host a conference call and audio webcast at 8:30 a.m. ET on Thursday, August 4, 2016 to discuss the financial results and recent business developments.
KPTI: 10.62 (-0.48)
Karyopharm to Present Updated Phase 2 Clinical Data from SIGN Study at European Society of Medical Oncology 2016 Annual Meeting
GlobeNewswire - Wed Jul 27, 3:05PM CDT
- Oral Presentation Describing Efficacy of Selinexor in Gynecological Cancers -
KPTI: 10.62 (-0.48)
Karyopharm Initiates Phase 1 Clinical Trial with KPT-9274
GlobeNewswire - Wed Jun 22, 6:30AM CDT
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced dosing of the first patient in a Phase 1 clinical trial evaluating KPT-9274, an oral, first-in-class, dual-acting p21-activated kinase 4 (PAK4) and nicotinamide phosphoribosyltransferase (NAMPT) inhibitor, in patients with advanced solid malignancies (including sarcoma, colon and lung cancer) or non-Hodgkin's lymphoma (NHL) whose disease has relapsed after standard therapy(s) (NCT02702492).
KPTI: 10.62 (-0.48)
Karyopharm Outlines Key Selinexor Clinical Development Achievements
GlobeNewswire - Thu Jun 16, 6:30AM CDT
- Enrollment Complete in Phase 2b STORM Clinical Trial in Multiple Myeloma -
KPTI: 10.62 (-0.48)
Karyopharm to Present at the 2016 JMP Securities Life Science Conference
GlobeNewswire - Wed Jun 15, 6:30AM CDT
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Michael G. Kauffmann, MD, PhD, Chief Executive Officer, will present at the 2016 JMP Securities Life Sciences Conference on Wednesday, June 22, 2016 at 2:00 p.m. E.T. The conference will be held at the St. Regis Hotel in New York.
KPTI: 10.62 (-0.48)
Karyopharm Presents Preliminary STOMP Phase 1b Clinical Data at 2016 European Hematology Association Annual Meeting
GlobeNewswire - Fri Jun 10, 6:30AM CDT
- Updated Clinical Data Shows High Response Rates When Selinexor Is Combined with Standard of Care Agents in Heavily Pretreated Patients with Multiple Myeloma -
KPTI: 10.62 (-0.48)
Karyopharm to Present at the Jefferies 2016 Healthcare Conference
GlobeNewswire - Wed Jun 01, 7:00AM CDT
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Justin A. Renz, Chief Financial Officer of Karyopharm, is scheduled to present at the upcoming Jefferies 2016 Healthcare Conference in New York City on Wednesday, June 8, 2016 at 3:00 p.m. ET.
KPTI: 10.62 (-0.48)
Karyopharm to Present Preliminary STOMP Phase 1B Clinical Data at 2016 European Hematology Association Annual Meeting
GlobeNewswire - Thu May 19, 6:30AM CDT
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that an abstract describing preliminary activity of selinexor (KPT-330) and dexamethasone in combination with bortezomib (Velcade(R)), pomalidomide (Pomalyst(R)), or lenalidomide (Revlimid(R)) for the treatment of relapsed/refractory multiple myeloma (MM) (the STOMP study) has been accepted for presentation at the 21 Congress of the European Hematology Association (EHA) held June 9-12, 2016 in Copenhagen, Denmark. The abstract describes preliminary Phase 1b data in which responses were observed with selinexor, Karyopharm's first-in-class, oral Selective Inhibitor of Nuclear Export / SINE(TM) compound that inhibits exportin 1 (XPO1), and dexamethasone in combination with standard of care MM therapies in patients with heavily pretreated MM. Updated and detailed results from the study will be presented at the conference.
KPTI: 10.62 (-0.48)
Karyopharm to Present Selinexor Clinical Data at the American Society of Clinical Oncology Annual Meeting
GlobeNewswire - Wed May 18, 4:40PM CDT
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that three abstracts involving selinexor (KPT-330), the Company's lead product candidate selinexor in development for hematological malignancies and solid tumors, have been selected for two poster presentations and one poster discussion at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 3-7 in Chicago. Updated and detailed results from these studies will be presented at the conference. The abstracts, which represent both company- and investigator-sponsored clinical studies, describe data related to selinexor, Karyopharm's first-in-class, oral Selective Inhibitor of Nuclear Export / SINE(TM) compound that inhibits exportin 1 (XPO1). Posters to be presented include a Phase 2 clinical update with single-agent selinexor in recurrent glioblastoma, Phase 2 study design of single-agent selinexor in advanced liposarcoma and Phase 1 data for selinexor in multiple myeloma in combination with liposomal doxorubicin and dexamethasone.
KPTI: 10.62 (-0.48)
Karyopharm Therapeutics posts 1Q loss
Automated Insights - Mon May 09, 6:47AM CDT
NEWTON, Mass. (AP) _ Karyopharm Therapeutics Inc. (KPTI) on Monday reported a loss of $27.1 million in its first quarter.
KPTI: 10.62 (-0.48)
Karyopharm Reports First Quarter 2016 Financial Results and Highlights Recent Progress
GlobeNewswire - Mon May 09, 6:30AM CDT
Phase 2/3 SEAL Clinical Trial Initiated with Selinexor for Treatment of Liposarcoma
KPTI: 10.62 (-0.48)
Why Earnings Season Could Be Great for Karyopharm Therapeutics (KPTI)
Zacks Equity Research - Zacks Investment Research - Fri May 06, 7:54AM CDT
Karyopharm Therapeutics (KPTI) looks like an exciting pick for investors as it is poised to beat at earnings season.
KPTI: 10.62 (-0.48)
Quanta Services (PWR) Q1 Earnings: Will It Disappoint?
Zacks Equity Research - Zacks Investment Research - Tue May 03, 3:52PM CDT
Quanta Services (PWR) is expected to report first-quarter 2016 results on May 5. Let's see how things are shaping up for this announcement.
PWR: 26.16 (+0.42), PEGI: 24.27 (+0.40), AMID: 14.28 (+0.66), KPTI: 10.62 (-0.48)
Match Group (MTCH) Q1 Earnings Preview: What to Expect
Zacks Equity Research - Zacks Investment Research - Mon May 02, 6:04PM CDT
Match Group (MTCH) is set to report first-quarter 2016 earnings results after the closing bell on May 3. Let's see how things are shaping up for this announcement.
MTCH: 16.04 (+0.16), PEGI: 24.27 (+0.40), AMID: 14.28 (+0.66), KPTI: 10.62 (-0.48)
Karyopharm to Report First Quarter 2016 Financial Results on May 9, 2016
GlobeNewswire - Mon May 02, 7:00AM CDT
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that it will report first quarter 2016 financial results and provide a company update on Monday, May 9, 2016. Karyopharm's management team will host a conference call and audio webcast at 8:30 a.m. ET on Monday, May 9, 2016 to discuss the financial results and recent business developments.
KPTI: 10.62 (-0.48)
Karyopharm Presents Data Demonstrating the Potential of Nuclear Export Protein Exportin 1 (XPO1) Inhibition in the Treatment of Traumatic Brain Injury
GlobeNewswire - Wed Apr 20, 6:00AM CDT
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced preclinical data demonstrating the activity of its Selective Inhibitor of Nuclear Export (SINE) compound, KPT-350, in rodent models of traumatic brain injury (TBI). These data were presented at the 2016 Annual Meeting of the American Academy of Neurology (AAN) taking place April 15-21 in Vancouver, Canada.
KPTI: 10.62 (-0.48)
Traumatic Brain Injury Pipeline Market 2016 Covering 37 Key Players
PR Newswire - Fri Apr 08, 5:00AM CDT
This 2016 report provides an overview of the Traumatic Brain Injury therapeutic pipeline and helps enhance decision making capabilities to create effective counter strategies & gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
LPTN: 2.35 (-0.02), OMER: 11.10 (+0.34), ATHX: 1.91 (-0.03), KPTI: 10.62 (-0.48), CUR: 0.25 (-0.02)
Karyopharm to Host Conference Call with Update on Multiple Myeloma Plans
GlobeNewswire - Tue Aug 30, 11:14AM CDT
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced it will provide an overview of top-line results from its Phase 2b STORM study and the planned development path for selinexor (KPT-330) in multiple myeloma (MM) on Tuesday, September 6, 2016, followed by a conference call on Tuesday, September 6, 2016 at 8:30 a.m., Eastern time. To access the conference call, please dial (855) 437-4406 (US) or (484) 756-4292 (international) at least five minutes prior to the start time and refer to conference ID: 74213103. Accompanying slides will be available under "Events & Presentations" in the "Investor" section of Karyopharm's website, http://www.karyopharm.com, where an audio recording of the call will be available approximately two hours after the event.
KPTI: 10.62 (-0.48)
Karyopharm Reports Second Quarter 2016 Financial Results and Highlights Recent Progress
GlobeNewswire - Thu Aug 04, 6:30AM CDT
Completed Enrollment in Phase 2b STORM Clinical Trial for Refractory Multiple Myeloma
KPTI: 10.62 (-0.48)
Karyopharm to Present at Upcoming Investor Conferences
GlobeNewswire - Wed Aug 03, 6:30AM CDT
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that members of the management team will present at the following upcoming investor conferences:
KPTI: 10.62 (-0.48)
Karyopharm to Report Second Quarter 2016 Financial Results on August 4, 2016
GlobeNewswire - Thu Jul 28, 7:00AM CDT
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that it will report second quarter 2016 financial results and provide a company update on Thursday, August 4, 2016. Karyopharm's management team will host a conference call and audio webcast at 8:30 a.m. ET on Thursday, August 4, 2016 to discuss the financial results and recent business developments.
KPTI: 10.62 (-0.48)
Karyopharm to Present Updated Phase 2 Clinical Data from SIGN Study at European Society of Medical Oncology 2016 Annual Meeting
GlobeNewswire - Wed Jul 27, 3:05PM CDT
- Oral Presentation Describing Efficacy of Selinexor in Gynecological Cancers -
KPTI: 10.62 (-0.48)
Karyopharm Initiates Phase 1 Clinical Trial with KPT-9274
GlobeNewswire - Wed Jun 22, 6:30AM CDT
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced dosing of the first patient in a Phase 1 clinical trial evaluating KPT-9274, an oral, first-in-class, dual-acting p21-activated kinase 4 (PAK4) and nicotinamide phosphoribosyltransferase (NAMPT) inhibitor, in patients with advanced solid malignancies (including sarcoma, colon and lung cancer) or non-Hodgkin's lymphoma (NHL) whose disease has relapsed after standard therapy(s) (NCT02702492).
KPTI: 10.62 (-0.48)
Karyopharm Outlines Key Selinexor Clinical Development Achievements
GlobeNewswire - Thu Jun 16, 6:30AM CDT
- Enrollment Complete in Phase 2b STORM Clinical Trial in Multiple Myeloma -
KPTI: 10.62 (-0.48)
Karyopharm to Present at the 2016 JMP Securities Life Science Conference
GlobeNewswire - Wed Jun 15, 6:30AM CDT
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Michael G. Kauffmann, MD, PhD, Chief Executive Officer, will present at the 2016 JMP Securities Life Sciences Conference on Wednesday, June 22, 2016 at 2:00 p.m. E.T. The conference will be held at the St. Regis Hotel in New York.
KPTI: 10.62 (-0.48)
Karyopharm Presents Preliminary STOMP Phase 1b Clinical Data at 2016 European Hematology Association Annual Meeting
GlobeNewswire - Fri Jun 10, 6:30AM CDT
- Updated Clinical Data Shows High Response Rates When Selinexor Is Combined with Standard of Care Agents in Heavily Pretreated Patients with Multiple Myeloma -
KPTI: 10.62 (-0.48)
Karyopharm to Present at the Jefferies 2016 Healthcare Conference
GlobeNewswire - Wed Jun 01, 7:00AM CDT
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Justin A. Renz, Chief Financial Officer of Karyopharm, is scheduled to present at the upcoming Jefferies 2016 Healthcare Conference in New York City on Wednesday, June 8, 2016 at 3:00 p.m. ET.
KPTI: 10.62 (-0.48)
Karyopharm to Present Preliminary STOMP Phase 1B Clinical Data at 2016 European Hematology Association Annual Meeting
GlobeNewswire - Thu May 19, 6:30AM CDT
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that an abstract describing preliminary activity of selinexor (KPT-330) and dexamethasone in combination with bortezomib (Velcade(R)), pomalidomide (Pomalyst(R)), or lenalidomide (Revlimid(R)) for the treatment of relapsed/refractory multiple myeloma (MM) (the STOMP study) has been accepted for presentation at the 21 Congress of the European Hematology Association (EHA) held June 9-12, 2016 in Copenhagen, Denmark. The abstract describes preliminary Phase 1b data in which responses were observed with selinexor, Karyopharm's first-in-class, oral Selective Inhibitor of Nuclear Export / SINE(TM) compound that inhibits exportin 1 (XPO1), and dexamethasone in combination with standard of care MM therapies in patients with heavily pretreated MM. Updated and detailed results from the study will be presented at the conference.
KPTI: 10.62 (-0.48)
Karyopharm to Present Selinexor Clinical Data at the American Society of Clinical Oncology Annual Meeting
GlobeNewswire - Wed May 18, 4:40PM CDT
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that three abstracts involving selinexor (KPT-330), the Company's lead product candidate selinexor in development for hematological malignancies and solid tumors, have been selected for two poster presentations and one poster discussion at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 3-7 in Chicago. Updated and detailed results from these studies will be presented at the conference. The abstracts, which represent both company- and investigator-sponsored clinical studies, describe data related to selinexor, Karyopharm's first-in-class, oral Selective Inhibitor of Nuclear Export / SINE(TM) compound that inhibits exportin 1 (XPO1). Posters to be presented include a Phase 2 clinical update with single-agent selinexor in recurrent glioblastoma, Phase 2 study design of single-agent selinexor in advanced liposarcoma and Phase 1 data for selinexor in multiple myeloma in combination with liposomal doxorubicin and dexamethasone.
KPTI: 10.62 (-0.48)
Karyopharm Therapeutics posts 1Q loss
Automated Insights - Mon May 09, 6:47AM CDT
NEWTON, Mass. (AP) _ Karyopharm Therapeutics Inc. (KPTI) on Monday reported a loss of $27.1 million in its first quarter.
KPTI: 10.62 (-0.48)
Karyopharm Reports First Quarter 2016 Financial Results and Highlights Recent Progress
GlobeNewswire - Mon May 09, 6:30AM CDT
Phase 2/3 SEAL Clinical Trial Initiated with Selinexor for Treatment of Liposarcoma
KPTI: 10.62 (-0.48)
Why Earnings Season Could Be Great for Karyopharm Therapeutics (KPTI)
Zacks Equity Research - Zacks Investment Research - Fri May 06, 7:54AM CDT
Karyopharm Therapeutics (KPTI) looks like an exciting pick for investors as it is poised to beat at earnings season.
KPTI: 10.62 (-0.48)
Quanta Services (PWR) Q1 Earnings: Will It Disappoint?
Zacks Equity Research - Zacks Investment Research - Tue May 03, 3:52PM CDT
Quanta Services (PWR) is expected to report first-quarter 2016 results on May 5. Let's see how things are shaping up for this announcement.
PWR: 26.16 (+0.42), PEGI: 24.27 (+0.40), AMID: 14.28 (+0.66), KPTI: 10.62 (-0.48)
Match Group (MTCH) Q1 Earnings Preview: What to Expect
Zacks Equity Research - Zacks Investment Research - Mon May 02, 6:04PM CDT
Match Group (MTCH) is set to report first-quarter 2016 earnings results after the closing bell on May 3. Let's see how things are shaping up for this announcement.
MTCH: 16.04 (+0.16), PEGI: 24.27 (+0.40), AMID: 14.28 (+0.66), KPTI: 10.62 (-0.48)
Karyopharm to Report First Quarter 2016 Financial Results on May 9, 2016
GlobeNewswire - Mon May 02, 7:00AM CDT
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that it will report first quarter 2016 financial results and provide a company update on Monday, May 9, 2016. Karyopharm's management team will host a conference call and audio webcast at 8:30 a.m. ET on Monday, May 9, 2016 to discuss the financial results and recent business developments.
KPTI: 10.62 (-0.48)
Karyopharm Presents Data Demonstrating the Potential of Nuclear Export Protein Exportin 1 (XPO1) Inhibition in the Treatment of Traumatic Brain Injury
GlobeNewswire - Wed Apr 20, 6:00AM CDT
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced preclinical data demonstrating the activity of its Selective Inhibitor of Nuclear Export (SINE) compound, KPT-350, in rodent models of traumatic brain injury (TBI). These data were presented at the 2016 Annual Meeting of the American Academy of Neurology (AAN) taking place April 15-21 in Vancouver, Canada.
KPTI: 10.62 (-0.48)
Traumatic Brain Injury Pipeline Market 2016 Covering 37 Key Players
PR Newswire - Fri Apr 08, 5:00AM CDT
This 2016 report provides an overview of the Traumatic Brain Injury therapeutic pipeline and helps enhance decision making capabilities to create effective counter strategies & gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
LPTN: 2.35 (-0.02), OMER: 11.10 (+0.34), ATHX: 1.91 (-0.03), KPTI: 10.62 (-0.48), CUR: 0.25 (-0.02)
(0)
(0)Scroll down for more posts ▼